534 related articles for article (PubMed ID: 26571021)
1. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S
PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021
[TBL] [Abstract][Full Text] [Related]
2. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
Kingston NJ; Kurtovic L; Walsh R; Joe C; Lovrecz G; Locarnini S; Beeson JG; Netter HJ
Vaccine; 2019 Mar; 37(12):1674-1684. PubMed ID: 30773400
[TBL] [Abstract][Full Text] [Related]
4. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
5. Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes.
Phares TW; May AD; Genito CJ; Hoyt NA; Khan FA; Porter MD; DeBot M; Waters NC; Saudan P; Dutta S
Malar J; 2017 Mar; 16(1):115. PubMed ID: 28288639
[TBL] [Abstract][Full Text] [Related]
6. Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice.
Kastenmüller K; Espinosa DA; Trager L; Stoyanov C; Salazar AM; Pokalwar S; Singh S; Dutta S; Ockenhouse CF; Zavala F; Seder RA
Infect Immun; 2013 Mar; 81(3):789-800. PubMed ID: 23275094
[TBL] [Abstract][Full Text] [Related]
7. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.
Przysiecki C; Lucas B; Mitchell R; Carapau D; Wen Z; Xu H; Wang XM; Nahas D; Wu C; Hepler R; Ottinger E; Ter Meulen J; Kaslow D; Shiver J; Nardin E
Front Cell Infect Microbiol; 2012; 2():146. PubMed ID: 23226683
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
[TBL] [Abstract][Full Text] [Related]
9. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
[TBL] [Abstract][Full Text] [Related]
10. [Production and molecular characterization of Plasmodium falciparum recombinant circumsporozoite protein with 37 NANP and 4 NVDP epitopes].
Uyar Y; Akşit A; Karaca S; Ceylan ŞS; Yürük M
Mikrobiyol Bul; 2017 Jan; 51(1):41-51. PubMed ID: 28283009
[TBL] [Abstract][Full Text] [Related]
11. Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of
Kurtovic L; Wetzel D; Reiling L; Drew DR; Palmer C; Kouskousis B; Hanssen E; Wines BD; Hogarth PM; Suckow M; Jenzelewski V; Piontek M; Chan JA; Beeson JG
Front Immunol; 2021; 12():641421. PubMed ID: 33815393
[TBL] [Abstract][Full Text] [Related]
12. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.
Noe AR; Espinosa D; Li X; Coelho-Dos-Reis JG; Funakoshi R; Giardina S; Jin H; Retallack DM; Haverstock R; Allen JR; Vedvick TS; Fox CB; Reed SG; Ayala R; Roberts B; Winram SB; Sacci J; Tsuji M; Zavala F; Gutierrez GM
PLoS One; 2014; 9(9):e107764. PubMed ID: 25247295
[TBL] [Abstract][Full Text] [Related]
13. Optimization of a
Langowski MD; Khan FA; Bitzer AA; Genito CJ; Schrader AJ; Martin ML; Soto K; Zou X; Hadiwidjojo S; Beck Z; Matyas GR; Livingstone MC; Batchelor AH; Dutta S
Proc Natl Acad Sci U S A; 2020 Feb; 117(6):3114-3122. PubMed ID: 31988134
[No Abstract] [Full Text] [Related]
14. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint.
Porter MD; Nicki J; Pool CD; DeBot M; Illam RM; Brando C; Bozick B; De La Vega P; Angra D; Spaccapelo R; Crisanti A; Murphy JR; Bennett JW; Schwenk RJ; Ockenhouse CF; Dutta S
Clin Vaccine Immunol; 2013 Jun; 20(6):803-10. PubMed ID: 23536694
[TBL] [Abstract][Full Text] [Related]
15. A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.
Radin K; Clement F; Jongert E; Sterckx YG; Ockenhouse C; Regules J; Lemiale F; Leroux-Roels G
Malar J; 2016 Nov; 15(1):543. PubMed ID: 27825382
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for antibody recognition of the NANP repeats in
Oyen D; Torres JL; Wille-Reece U; Ockenhouse CF; Emerling D; Glanville J; Volkmuth W; Flores-Garcia Y; Zavala F; Ward AB; King CR; Wilson IA
Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10438-E10445. PubMed ID: 29138320
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
[TBL] [Abstract][Full Text] [Related]
18. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
[TBL] [Abstract][Full Text] [Related]
19. Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus.
Urakami A; Sakurai A; Ishikawa M; Yap ML; Flores-Garcia Y; Haseda Y; Aoshi T; Zavala FP; Rossmann MG; Kuno S; Ueno R; Akahata W
Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28515133
[TBL] [Abstract][Full Text] [Related]
20. Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies.
Triller G; Scally SW; Costa G; Pissarev M; Kreschel C; Bosch A; Marois E; Sack BK; Murugan R; Salman AM; Janse CJ; Khan SM; Kappe SHI; Adegnika AA; Mordmüller B; Levashina EA; Julien JP; Wardemann H
Immunity; 2017 Dec; 47(6):1197-1209.e10. PubMed ID: 29195810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
